Hot on the heels of FLOW:

What are the effects of SGLT2i on clinical outcomes with and without GLP-1RA? 🧵

Over 3,000 patients receiving GLP-1RA at baseline in SGLT2i Trialists' Consortium (SMART-C)

#ERA24 @ERAkidney





Patients receiving & not receiving GLP-1RA were generally similar but those on GLP-1RA at baseline were less likely to be female, have a history of heart failure, had a higher BMI, and were more likely to be receiving insulin

#ERA24 @ERAkidney

New insights from the CREDENCE trial on the blood pressure lowering effects of canagliflozin in type 2 diabetes and CKD now published in @CircAHA

ahajournals.org/doi/abs/10.116… Of all the major SGLT2i trials, CREDENCE had perhaps the highest burden of hypertension, which gave us the unique opportunity to assess the BP effects of SGLT2 inhibition in CKD

Of 4401 patients:
-25% systolic BP>150 at baseline
-30% resistant HTN
-20% on 4+ BP lowering agents

Very proud to present this late breaking clinical trials poster at #KidneyWk:

The largest randomised individual participant data analysis of any #SGLT2 inhibitor to date

🧵 A summary thread: Why is this analysis important?

1. Composite cardiorenal outcomes are clinically important but have not been consistently reported in trials of SGLT2 inhibitors - Figure from @RangaswJ et al. in @CircAHA #KidneyWk